title: [Curative Effects of Hydroxyurea on the Patients with β-thalassaemia Intermadia].
abstract: OBJECTIVE
  To investigate the clinical features of β-thalassaemia intermediate (TI) patients and the curative effect and side reactions of hydroxyurea therapys.
  
  
  METHODS
  Twenty nine patients with TI were divided into hydroxyurea therapy group and no hydroxyurea therapy group; the curative effect and side reactions in 2 groups were compared; the situation of blood transfusion in the 2 groups was evaluated.
  
  
  RESULTS
  In hydroxyurea therapy group, the hemoglobin level increased after treatment for 3 months; the reticulocyte percentage obviously decreased after treatment for 12 months; the serum ferritin had been maintained at a low level; while in no hydroxyurea therapy group, the levels of hemoglobin and reticulocytes were not significantly improved after treatment, the serum ferritin level gradually increased. In hydroxyurea therapy group, 12 cases were out of blood transfusion after treatment for 12 months, effective rate of treatment was 85.71%; while in no hydroxyurea therapy group, the blood transfusion dependency was not improved after treatment. No serious side reactions were found in all the hydroxyurea treated patients.
  
  
  CONCLUSIONS
  The hydroxyurea shows a better curative effect on TI patients, no serious side reactions occur in all the patients treated with hydroxyurea, but the long-term curative effect and side reactions should be observed continuously.
authors.affiliation: Department of Hematology, People's Hospital of Hainan Province, Haikou 570311, Hainan Province, China.
authors.forename: Li
authors.initials: L
authors.lastname: Huang
authors.affiliation: Department of Hematology, People's Hospital of Hainan Province, Haikou 570311, Hainan Province, China. E-mail: yaohongxia768@gmail.com.
authors.forename: Hong-Xia
authors.initials: HX
authors.lastname: Yao
mesh_terms: D001803:Blood Transfusion; D005293:Ferritins / Q000032:analysis; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D012156:Reticulocytes / Q000166:cytology; D016896:Treatment Outcome; D017086:beta-Thalassemia / Q000188:drug therapy*
chemical_list: D006454:Hemoglobins; D005293:Ferritins; D006918:Hydroxyurea